Anthem Biosciences Ltd Sector Top 20
Integrated contract research, development, and manufacturing organisation serving pharmaceutical and biotechnology programs across discovery, development, and commercial manufacturing.
Valuation
Returns
Per share
Growth · year on year
Ownership
Price and ratios are compiled from the exchange and third-party market data, cached and refreshed through the day — they are not Atlas facts and are not investment advice. Where a ratio is computed on more than one basis (for example standalone versus trailing-twelve-month), each is shown separately rather than averaged into a single number.
How this score is calculated
| Measure | Value | Scores | Source |
|---|---|---|---|
| P/E What the market pays for each rupee of earnings. Lower is cheaper — but a low P/E can also mean the market expects earnings to fall. Computed on a different basis this reads 80.24, which would score 0/100. Scored on the figure shown. |
50.03 | 25/100 | BSE |
| P/B Price against book value. Most meaningful for banks and asset-heavy businesses; software and consumer brands trade high here for good reasons. |
15.39 | 0/100 | Market data |
| ROE Return on equity — profit generated per rupee of shareholder capital. Sustained high ROE is the clearest single marker of a good business. |
23.99 | 100/100 | Market data |
| ROCE Return on capital employed — the same idea including debt, so it is harder to flatter with leverage. |
31.30 | 100/100 | Market data |
| Profit growth Year-on-year growth in profit. Weighted above sales growth because profitable growth is the harder thing to do. |
32.47 | 100/100 | Market data |
| Sales growth Year-on-year growth in revenue. |
13.51 | 75/100 | Market data |
| Promoter holding How much of the company its founders and controlling group still own. Higher usually means their money moves with yours. |
71.42 | 100/100 | Market data |
The Atlas Score is our own arithmetic on the published figures above — nothing is hidden and nothing is bought in. It weighs quality and growth at 30% each, valuation at 25% and ownership at 15%, scoring each measure against fixed bands. Growth blends third-party market data with the fiscal-year figures we file and cite ourselves, so a company we have researched more deeply scores on richer evidence. A measure we could not fetch is left out of the average rather than counted as a zero. It is a summary of the numbers, not a recommendation, not a price target, and not advice about your circumstances.
Anthem Biosciences Ltd: Funding Rounds
No funding rounds tracked for Anthem Biosciences Ltd yet.
News on Anthem Biosciences Ltd
No coverage of Anthem Biosciences Ltd linked yet.
L Litmus · by Lapaas
Got an idea like this one? Validate it with the same 9-block framework, free.
Start Free ValidationFAQs on Anthem Biosciences Ltd
What does Anthem Biosciences Ltd do?
Integrated contract research, development, and manufacturing organisation serving pharmaceutical and biotechnology programs across discovery, development, and commercial manufacturing.